A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Eli Lilly and Company
Blueprint Medicines Corporation
Inspirna, Inc.
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sanofi